`
`A senate of the National Library of Medicine
`and the National institutes of Health
`
`1” 1: Hinyokika Kiyo. 1994 Mar;40(3):279—84.
`
`[Study on clinical effects of tosufloxacin (TFLX) and the long-term low
`dose therapy for the prophylaxis of recurrent urinary tract infection]
`
`[Article in Japanese]
`
`Sakurai M, Sugimura.Y, Arjm_a..K, Kawamura 1, Saitou K, Tajirna
`N__a..kano.S, Sat.a,n.i, H. Naga.n_o,,M, H,,o,s_h,ina A, et al-
`
`Department of Urology, Mie University School of Medicine.
`
`Forty five patients with complicated urinary tract infections were treated
`with tosufloxacin (TFLX) in the initial antibacterial treatment. Excellent
`and moderate responses were obtained in 39 patients (86.7%). No side
`effects were seen. Clinical efficacy and safety of long—term preventive
`administration of TFLX (150mg, a day) were also examined in 39
`patients who showed an excellent or a moderate response in the initial
`treatment. The period of the administration ranged from 28 to 112 days V
`(average; 55 days). The rate of preventing recurrence of urinary tract
`infection was 92.3% on the last day of treatment. These findings
`suggested that TFLX was useful not only in treating the patients with
`complicated urinary tract infections but also in preventing recurrence of
`urinary tract infection.
`
`PMID: 8178752 [PubMed - indexed for MEDLINE]
`
`ALCON 2106
`Apotex Inc. v. Alcon Pharmaceuticals, Ltd.
`Case |PR2013-00012
`
`